A new study published in the Journal of Perinatology turns its attention to precisely this problem, asking whether clinicians can identify, early in a hospital stay, which infants with gastroschisis are most likely to develop serious infections. The research, available at https://doi.org/10.1038/s41372-026-02880-x, reflects a broader movement in neonatology toward risk prediction models that move care away from a one-size-fits-all approach and toward individualized surveillance. For a condition as variable as gastroschisis, where two infants of similar birth weight can follow dramatically different clinical courses, the ability to stratify risk at the bedside could reshape how intensively each baby is monitored and how quickly clinicians respond to subtle warning signs.

The clinical stakes are considerable. Neonates with gastroschisis are routinely exposed to a dense constellation of infection risks. Central venous catheters, which are essential for delivering parenteral nutrition while the injured bowel recovers its function, are a well-established gateway for bloodstream infections. Prolonged fasting leaves the gut barrier compromised. Repeated operations, open abdominal wounds, and lengthy intensive care stays each add further opportunities for bacterial colonization and invasion. Inflammatory responses triggered by the exposed bowel itself can blur the line between expected postoperative inflammation and the earliest signs of sepsis, making diagnosis notoriously difficult in this population.

This diagnostic ambiguity is one of the central reasons why predictive modeling has become such an active frontier in neonatal research. In a typical newborn, fever, lethargy, and abnormal blood counts prompt a sepsis evaluation and often empiric antibiotics. In an infant recovering from gastroschisis repair, however, many of those same signals can arise from the surgical insult or from the impaired gut motility that almost universally follows. C-reactive protein levels, white blood cell counts, and platelet trends all shift in the days after abdominal surgery for reasons that have nothing to do with infection. Clinicians therefore walk a narrow line: treat too aggressively, and the infant faces the well-documented harms of unnecessary antibiotics, including disrupted microbiome development, fungal overgrowth, and selection for resistant organisms; treat too cautiously, and a true bloodstream infection can progress to septic shock with devastating speed.

Predictive tools attempt to resolve this tension by combining multiple clinical variables into a single, quantified estimate of risk. In the context of gastroschisis, such variables typically include gestational age at delivery, birth weight, the presence and severity of bowel complications such as atresia or volvulus, the type of abdominal closure achieved, the duration of mechanical ventilation, the length of time central catheters remain in place, and the interval before enteral feeding is tolerated. Laboratory markers, including serial inflammatory indices and culture results, add another layer of information. When these inputs are weighted appropriately, they can distinguish, with meaningful statistical separation, between infants whose postoperative course is following an expected trajectory and those whose trajectory has quietly diverged toward infection.

The methodology behind such models is as important as the models themselves. Robust prediction research requires large, well-characterized cohorts, careful handling of missing data, and honest internal and external validation. A model that performs impressively in the dataset used to build it but fails when applied to a different hospital’s population is of little clinical value, a phenomenon researchers call overfitting. Modern approaches increasingly incorporate penalized regression techniques, which constrain model complexity to improve generalizability, and some groups have begun exploring machine learning classifiers that can capture nonlinear interactions among variables. Whatever the statistical engine, the output must ultimately be interpretable at the bedside: a neonatologist at three in the morning needs a number, a trend, and a clear sense of what action that number should prompt.

For infants with gastroschisis, the practical payoff of reliable risk prediction would extend across the entire care pathway. Infants flagged as high risk could be prioritized for earlier and more frequent laboratory surveillance, stricter catheter hygiene protocols, or prophylactic strategies that are currently reserved for the most vulnerable patients. Nursing teams could adjust monitoring intervals, and antimicrobial stewardship programs could use risk scores to decide when empiric therapy is justified and when watchful waiting is safe. Conversely, infants identified as low risk could potentially avoid some of the cascades of testing and treatment that prolong intensive care stays and expose newborns to unnecessary interventions. In an era when neonatal units are under constant pressure to improve outcomes while reducing iatrogenic harm, this kind of stratification is exactly the kind of tool that translates epidemiological insight into bedside benefit.

The study also arrives at a moment of genuine progress in gastroschisis outcomes overall. Survival for isolated gastroschisis in high-resource settings now exceeds ninety percent, and the majority of infants go on to normal growth and development. But morbidity remains stubbornly high, and infection is consistently among the leading drivers of prolonged hospitalization, repeated imaging, extended parenteral nutrition, and delayed discharge. Every week of hospitalization carries costs, both financial and developmental, since prolonged neonatal intensive care separates infants from their families during a critical window of bonding and neurodevelopment. Reducing infection-related morbidity is therefore not merely a matter of preventing acute crises; it is a lever for shortening stays, accelerating family-centered care, and improving the long-term trajectory of these children.

There are, of course, important caveats that temper enthusiasm. Prediction is not prevention. A risk score, however accurate, does not by itself lower infection rates; it must be coupled to interventions that change management, and those interventions must themselves be proven effective in this specific population. Questions of equity also deserve attention, since models trained on data from a small number of centers may perform differently across diverse populations, and gastroschisis incidence varies notably by maternal age and socioeconomic factors, with the condition occurring more frequently in younger mothers. Any predictive tool intended for broad clinical use will need validation across geographically and demographically varied cohorts before it can be trusted to guide care universally.

Still, the direction of travel is clear. Neonatology is steadily accumulating the large, granular datasets needed to build dependable prognostic instruments, and gastroschisis, with its well-defined population and its concentrated period of high risk, is an ideal candidate for this kind of precision approach. The Journal of Perinatology study adds to a growing evidence base suggesting that the complications of congenital surgical conditions need not be met with reactive medicine alone. If clinicians can reliably forecast which infants are sliding toward infection before the first positive culture returns, the window for effective intervention opens days earlier, and days matter enormously in the life of a newborn. For the families who spend anxious weeks at the incubator’s side, and for the clinicians who care for them, that earlier warning could make the difference between a complication and a catastrophe, between a prolonged stay and a safe journey home.

Subject of Research: Predicting infection risk in infants with gastroschisis

Article Title: Predicting risk of infection in infants with gastroschisis

Article References: Predicting risk of infection in infants with gastroschisis. (n.d.). https://doi.org/10.1038/s41372-026-02880-x

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02880-x

Keywords: gastroschisis, neonatal infection, risk prediction, Journal of Perinatology, neonatal intensive care, sepsis, abdominal wall defect, central venous catheter, antimicrobial stewardship, predictive modeling, newborn surgery, neonatal outcomes

Group B Streptococcus, commonly abbreviated GBS or Streptococcus agalactiae, is a bacterium that can colonize the gastrointestinal and genital tracts without causing symptoms in adults. During pregnancy, however, a colonized mother can transmit the organism to her infant before, during or shortly after delivery. Most exposed babies remain healthy, but some develop invasive disease, in which bacteria enter normally sterile sites such as the bloodstream, lungs or central nervous system. In newborns, the consequences can be severe, including sepsis, pneumonia and meningitis. Clinicians generally divide GBS disease into early-onset disease, occurring during the first days of life, and late-onset disease, emerging later in infancy.

That classification is clinically useful, but it can also conceal important biological variation. A baby born prematurely does not enter the world with the same immune maturity, lung development, skin barrier function or microbial environment as a full-term infant. Prematurity may also change the duration and route of exposure to GBS, including whether transmission occurs before birth, during labor or after delivery. The new research focuses on this interaction, asking whether the association between a GBS strain’s genome and the age at which disease appears changes according to gestational age—the number of weeks of pregnancy completed before birth.

The investigators’ approach reflects a broader transformation in infectious-disease research. Instead of treating GBS as a single, uniform pathogen, genomic epidemiology views it as a population of related but genetically diverse bacterial lineages. Whole-genome sequencing can identify differences across bacterial strains, including their capsular types, sequence lineages and genes associated with colonization, immune evasion, toxin production, surface attachment or antimicrobial resistance. These features do not operate in isolation, and the presence of a gene does not automatically prove that it causes more severe disease. Nevertheless, genome-wide data can reveal patterns that are invisible when infections are classified only by symptoms or by the broad label of “GBS.”

The central finding signaled by the study is that gestational age modifies the relationship between genomic characteristics and postnatal age at disease onset. In statistical terms, gestational age functions as an effect modifier: the strength or direction of an association between bacterial genetic features and disease timing is not necessarily the same for preterm and full-term infants. This distinction is important. An effect modifier is not simply another risk factor added to a list; it changes how researchers must interpret the relationship between two variables. A strain characteristic associated with earlier disease in one gestational-age group may show a weaker association, or a different pattern, in another.

This finding offers a possible explanation for why efforts to identify universally “high-risk” GBS strains have often produced an incomplete picture. A bacterial lineage may be particularly successful at causing disease shortly after birth in infants whose immune systems and physiological barriers are still immature, while the same lineage may behave differently in more mature newborns. Conversely, genetic traits that matter during later infant disease could have less influence during the earliest hours of life, when exposure route, delivery circumstances and maternal-to-infant transmission may dominate. The bacterium’s genome remains important, but its effects are filtered through the developmental state of the host.

The study also highlights why gestational age must be integrated into genomic surveillance and clinical research rather than treated as a background demographic detail. Premature infants are already known to face elevated risks of infection because their immune responses are developing and because they often require invasive medical support. If particular GBS genomic profiles are linked to distinct onset patterns within specific gestational-age groups, future surveillance systems may be able to detect more precise warning signals. Such systems could combine maternal colonization data, neonatal symptoms, delivery history and bacterial sequencing to estimate which infants require especially close observation after birth.

The implications extend to prevention, although the research does not by itself create a new diagnostic test or treatment. Current prevention strategies include screening pregnant women for GBS colonization and administering antibiotics during labor when indicated. These measures have helped reduce many cases of early-onset disease, but they do not eliminate all infections, and they offer limited protection against disease that develops later. A clearer understanding of how bacterial genomes interact with fetal maturity could inform the design of vaccines, refine risk models and help researchers determine whether prevention should be tailored to particular bacterial lineages or clinical settings. It could also encourage more careful interpretation of studies that combine preterm and term infants into a single analysis.

For families and clinicians, the work reinforces a practical message: the timing of symptoms is biologically meaningful, but it should never be used to dismiss a newborn’s sudden deterioration. GBS sepsis can progress quickly, and signs such as poor feeding, breathing difficulty, unusual sleepiness, temperature instability or changes in muscle tone require urgent medical assessment. The study does not suggest that parents can identify dangerous strains themselves, nor does it imply that genomic information can replace clinical care. Instead, it shows why the same bacterial species can produce different disease trajectories in different newborns, and why a more personalized understanding of neonatal infection is becoming possible.

The broader lesson is that infectious disease is shaped by a three-way conversation between pathogen, host and time. GBS carries a genome that influences how it survives and spreads, but the newborn provides a changing biological environment, one that differs dramatically between a very premature infant and a baby born at term. By demonstrating that gestational age modifies associations between bacterial genomic characteristics and the postnatal timing of disease, Murra, Henriksen, Andersen and colleagues move the field beyond one-size-fits-all descriptions of neonatal GBS infection. Their work points toward a future in which genomic epidemiology is combined with developmental biology to explain not only who becomes infected, but also why disease emerges when it does.

Subject of Research: The interaction between Group B Streptococcus genomic characteristics, gestational age and the timing of neonatal disease onset.

Article Title: Gestational age modifies associations between Group B Streptococcus genomic characteristics and postnatal age at disease onset.

Article References: Murra, M., Henriksen, T.B., Andersen, M. et al. “Gestational age modifies associations between Group B Streptococcus genomic characteristics and postnatal age at disease onset.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76999-y

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76999-y

Keywords: Group B Streptococcus, neonatal sepsis, genomic epidemiology, gestational age, preterm infants, early-onset disease, late-onset disease, neonatal infection, whole-genome sequencing, bacterial genomics